Injectable Opioid Agonist Treatment

Presenters: Julie Foreman, RN BSN
Hope to Health Research and Innovation Centre, BC-CfE
Dr. Christy Sutherland, MD CCFP
Medical Director, PHS Community Services Society

Share this video:
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025